Mineralys Therapeutics, Inc. Common Stock

Mineralys is trading with a 13.28% short float—notably elevated for a biotech name—while RSI sits at 63.1, suggesting building momentum but not yet extreme overbought conditions. The absence of an earnings multiple (P/E: n/a) indicates the company remains unprofitable, typical for early-stage therapeutics where clinical catalysts drive valuation. At $2.6B market cap and positioned below its 52-week high, the stock appears to still have room to run if pipeline progress accelerates. The combination of elevated short interest and mid-range momentum creates potential for a volatile squeeze, particularly if near-term trial data proves positive, though the lack of profitability means clinical execution risk remains paramount.